Short-term folic acid use does not appear to increase cancer risk
Taken from The Lancet – by Bruce Sylvester – Short-term folic acid supplement use does not affect overall cancer risk and does little to increase the risk of… read more.
Taken from The Lancet – by Bruce Sylvester – Short-term folic acid supplement use does not affect overall cancer risk and does little to increase the risk of… read more.
It is well known that COPD patients run a higher risk of contracting respiratory infections. However, a new thesis from Lund University in Sweden shows that they are… read more.
An international group of scientists has identified three genetic regions that predispose Asian women who have never smoked to lung cancer.
Chronic obstructive pulmonary disease (COPD) and lung cancer are two of the most important smoking-related diseases worldwide, with a huge combined mortality burden.
As of 2009, the overall death rate for cancer in the United States had declined 20 percent from its peak in 1991, translating to the avoidance of approximately… read more.
World Health Matters – China – by Gary Finnegan – A study of nearly 6,000 people in five provinces in China has shown that people exposed to passive… read more.
Yet, researchers say lung cancer tests needed when making COPD diagnosis.
New research shows that one in seven or 15% of Irish people have an undiagnosed lung condition and that this figure doubles to almost 30% in people over… read more.
by Dr Aidan O’Brien, Consultant Respiratory Physician, Mid Western Regional Hospital, Limerick, Local Organiser of the ITS Meeting 2012 – State of the art developments in respiratory medicine… read more.
Proof-of-concept animal study selected as one of the best presentations at 54th American Society of Hematology Annual Meeting and Exposition.
There is no difference between proton radiotherapy (PRT) and intensity-modulated radiotherapy (IMRT) when comparing the toxicity among patients with prostate cancer at 12 months post-treatment according to a… read more.
by Marybeth Burke – Crizotinib demonstrated significant anti-tumour activity in patients with advanced non-small cell lung cancer (NSCLC) harbouring ROS1 rearrangements,